<table cellpadding="2" frame="void" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>TABLE 2: Effect of SINGULAIR on Asthma-Related Outcome Measurements (Combined Analyses - U.S. and Multinational Trials)</caption>
<col></col>
<col></col>
<col></col>
<thead>
<tr>
<td valign="top"> </td>
<td align="center" valign="top"> SINGULAIR </td>
<td align="center" valign="top"> Placebo </td>
</tr>
</thead>
<tbody>
<tr>
<td valign="top"> Asthma Attack<footnote id="FOOT_313">Asthma Attack defined as utilization of health-care resources such as an unscheduled visit to a doctor's office, emergency room, or hospital; or treatment with oral, intravenous, or intramuscular corticosteroid.</footnote> (% of patients) </td>
<td align="center" valign="top"> 11.6 <footnote id="FOOT_314">p&lt;0.001, compared with placebo</footnote>
</td>
<td align="center" valign="top"> 18.4 </td>
</tr>
<tr>
<td valign="top"> Oral Corticosteroid Rescue (% of patients) </td>
<td align="center" valign="top"> 10.7<footnoteref idref="FOOT_314"></footnoteref>
</td>
<td align="center" valign="top"> 17.5 </td>
</tr>
<tr>
<td valign="top"> Discontinuation Due to Asthma (% of patients) </td>
<td align="center" valign="top"> 1.4<footnote id="FOOT_315">p&lt;0.01, compared with placebo</footnote>
</td>
<td align="center" valign="top"> 4.0 </td>
</tr>
<tr>
<td valign="top"> Asthma Exacerbations<footnote id="FOOT_316">Asthma Exacerbation defined by specific clinically important decreases in PEFR, increase in β-agonist use, increases in day or nighttime symptoms, or the occurrence of an asthma attack.</footnote> (% of days)</td>
<td align="center" valign="top"> 12.8<footnoteref idref="FOOT_314"></footnoteref>
</td>
<td align="center" valign="top"> 20.5 </td>
</tr>
<tr>
<td valign="top"> Asthma Control Days<footnote id="FOOT_317">An Asthma Control Day defined as a day without any of the following: nocturnal awakening, use of more than 2 puffs of β-agonist, or an asthma attack.</footnote> (% of days) </td>
<td align="center" valign="top"> 38.5<footnoteref idref="FOOT_314"></footnoteref>
</td>
<td align="center" valign="top"> 27.2 </td>
</tr>
<tr>
<td valign="top"> Physicians’ Global Evaluation (score)<footnote id="FOOT_318">Physicians’ evaluation of the patient’s asthma, ranging from 0 to 6 (“very much better” through “very much worse”, respectively).</footnote>
</td>
<td align="center" valign="top"> 1.77<footnoteref idref="FOOT_314"></footnoteref>
</td>
<td align="center" valign="top"> 2.43</td>
</tr>
<tr>
<td valign="top"> Patients’ Global Evaluation (score)<footnote id="FOOT_319">Patients’ evaluation of asthma, ranging from 0 to 6 (“very much better” through “very much worse”, respectively).</footnote>
</td>
<td align="center" valign="top"> 1.60<footnoteref idref="FOOT_314"></footnoteref>
</td>
<td align="center" valign="top">  2.15</td>
</tr>
</tbody>
</table>